248 related articles for article (PubMed ID: 16085419)
21. Stereochemical diversity-oriented conformational restriction strategy. Development of potent histamine H3 and/or H4 receptor antagonists with an imidazolylcyclopropane structure.
Watanabe M; Kazuta Y; Hayashi H; Yamada S; Matsuda A; Shuto S
J Med Chem; 2006 Sep; 49(18):5587-96. PubMed ID: 16942032
[TBL] [Abstract][Full Text] [Related]
22. A new class of diamine-based human histamine H3 receptor antagonists: 4-(aminoalkoxy)benzylamines.
Apodaca R; Dvorak CA; Xiao W; Barbier AJ; Boggs JD; Wilson SJ; Lovenberg TW; Carruthers NI
J Med Chem; 2003 Aug; 46(18):3938-44. PubMed ID: 12930154
[TBL] [Abstract][Full Text] [Related]
23. H3-receptor antagonists: synthesis and structure-activity relationships of para- and meta-substituted 4(5)-phenyl-2-[[2-[4(5)-imidazolyl]ethyl]thio]imidazoles.
Mor M; Bordi F; Silva C; Rivara S; Crivori P; Plazzi PV; Ballabeni V; Caretta A; Barocelli E; Impicciatore M; Carrupt PA; Testa B
J Med Chem; 1997 Aug; 40(16):2571-8. PubMed ID: 9258364
[TBL] [Abstract][Full Text] [Related]
24. D-amino acid homopiperazine amides: discovery of A-320436, a potent and selective non-imidazole histamine H(3)-receptor antagonist.
Curtis MP; Dwight W; Pratt J; Cowart M; Esbenshade TA; Krueger KM; Fox GB; Pan JB; Pagano TG; Hancock AA; Faghih R; Bennani YL
Arch Pharm (Weinheim); 2004 Apr; 337(4):219-29. PubMed ID: 15146898
[TBL] [Abstract][Full Text] [Related]
25. [125I]iodoproxyfan and related compounds: a reversible radioligand and novel classes of antagonists with high affinity and selectivity for the histamine H3 receptor.
Stark H; Purand K; Hüls A; Ligneau X; Garbarg M; Schwartz JC; Schunack W
J Med Chem; 1996 Mar; 39(6):1220-6. PubMed ID: 8632428
[TBL] [Abstract][Full Text] [Related]
26. A new class of histamine H3 receptor antagonists derived from ligand based design.
Roche O; Rodríguez Sarmiento RM
Bioorg Med Chem Lett; 2007 Jul; 17(13):3670-5. PubMed ID: 17498953
[TBL] [Abstract][Full Text] [Related]
27. Analysis of structure-activity relationships for MT2 selective antagonists by melatonin MT1 and MT2 receptor models.
Rivara S; Lorenzi S; Mor M; Plazzi PV; Spadoni G; Bedini A; Tarzia G
J Med Chem; 2005 Jun; 48(12):4049-60. PubMed ID: 15943478
[TBL] [Abstract][Full Text] [Related]
28. Pharmacological and behavioral properties of A-349821, a selective and potent human histamine H3 receptor antagonist.
Esbenshade TA; Fox GB; Krueger KM; Baranowski JL; Miller TR; Kang CH; Denny LI; Witte DG; Yao BB; Pan JB; Faghih R; Bennani YL; Williams M; Hancock AA
Biochem Pharmacol; 2004 Sep; 68(5):933-45. PubMed ID: 15294456
[TBL] [Abstract][Full Text] [Related]
29. Substituted N-phenylcarbamates as histamine H3 receptor antagonists with improved in vivo potency.
Reidemeister S; Stark H; Ligneau X; Ganellin CR; Schwartz JC; Schunack W
Pharmazie; 2000 Feb; 55(2):83-6. PubMed ID: 10723763
[TBL] [Abstract][Full Text] [Related]
30. In vitro optimization of structure activity relationships of analogues of A-331440 combining radioligand receptor binding assays and micronucleus assays of potential antiobesity histamine H3 receptor antagonists.
Hancock AA; Diehl MS; Faghih R; Bush EN; Krueger KM; Krishna G; Miller TR; Wilcox DM; Nguyen P; Pratt JK; Cowart MD; Esbenshade TA; Jacobson PB
Basic Clin Pharmacol Toxicol; 2004 Sep; 95(3):144-52. PubMed ID: 15447739
[TBL] [Abstract][Full Text] [Related]
31. Histamine H3 receptor antagonists: from target identification to drug leads.
Bonaventure P; Letavic M; Dugovic C; Wilson S; Aluisio L; Pudiak C; Lord B; Mazur C; Kamme F; Nishino S; Carruthers N; Lovenberg T
Biochem Pharmacol; 2007 Apr; 73(8):1084-96. PubMed ID: 17129577
[TBL] [Abstract][Full Text] [Related]
32. Compared pharmacology of human histamine H3 and H4 receptors: structure-activity relationships of histamine derivatives.
Gbahou F; Vincent L; Humbert-Claude M; Tardivel-Lacombe J; Chabret C; Arrang JM
Br J Pharmacol; 2006 Apr; 147(7):744-54. PubMed ID: 16432504
[TBL] [Abstract][Full Text] [Related]
33. 1-alkyl-4-acylpiperazines as a new class of imidazole-free histamine H(3) receptor antagonists.
Zaragoza F; Stephensen H; Knudsen SM; Pridal L; Wulff BS; Rimvall K
J Med Chem; 2004 May; 47(11):2833-8. PubMed ID: 15139761
[TBL] [Abstract][Full Text] [Related]
34. Theophylline derivatives as potential histamine H3-receptor antagonists.
Kieć-Kononowicz K; Cegła MT
Pharmazie; 1998 Aug; 53(8):518-21. PubMed ID: 9741061
[TBL] [Abstract][Full Text] [Related]
35. 4-(omega-(alkyloxy)alkyl)-1H-imidazole derivatives as histamine H(3) receptor antagonists/agonists.
Meier G; Krause M; Hüls A; Ligneau X; Pertz HH; Arrang JM; Ganellin CR; Schwartz JC; Schunack W; Stark H
J Med Chem; 2004 May; 47(10):2678-87. PubMed ID: 15115409
[TBL] [Abstract][Full Text] [Related]
36. Benzimidazole-substituted (3-phenoxypropyl)amines as histamine H3 receptor ligands.
Aslanian R; Zhu X; Vaccaro HA; Shih NY; Piwinski JJ; Williams SM; West RE
Bioorg Med Chem Lett; 2008 Sep; 18(18):5032-6. PubMed ID: 18752952
[TBL] [Abstract][Full Text] [Related]
37. Imidazole H3-antagonists: relationship between structure and ex vivo binding to rat brain H3-receptors.
Vacondio F; Mor M; Silva C; Zuliani V; Rivara M; Rivara S; Bordi F; Plazzi PV; Magnanini F; Bertoni S; Ballabeni V; Barocelli E; Carrupt PA; Testa B
Eur J Pharm Sci; 2004 Sep; 23(1):89-98. PubMed ID: 15324926
[TBL] [Abstract][Full Text] [Related]
38. Three-dimensional model of the human urotensin-II receptor: docking of human urotensin-II and nonpeptide antagonists in the binding site and comparison with an antagonist pharmacophore model.
Lescot E; Sopkova-de Oliveira Santos J; Colloc'h N; Rodrigo J; Milazzo-Segalas I; Bureau R; Rault S
Proteins; 2008 Oct; 73(1):173-84. PubMed ID: 18409194
[TBL] [Abstract][Full Text] [Related]
39. A novel series of (phenoxyalkyl)imidazoles as potent H3-receptor histamine antagonists.
Ganellin CR; Fkyerat A; Bang-Andersen B; Athmani S; Tertiuk W; Garbarg M; Ligneau X; Schwartz JC
J Med Chem; 1996 Sep; 39(19):3806-13. PubMed ID: 8809168
[TBL] [Abstract][Full Text] [Related]
40. Piperidine-containing histamine H3 receptor antagonists of the carbamate series: the influence of the additional ether functionality.
Łazewska D; Kieć-Kononowicz K; Pertz HH; Elz S; Stark H; Schunack W
Pharmazie; 2002 Dec; 57(12):791-5. PubMed ID: 12561236
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
